GlassScriptPhysician profile
Paula A Amacker
NPI 1598916884
$5,979.85
in general payments reported to CMS, 2019-2025
29 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $980 · 2022: $1,627 · 2023: $1,442 · 2024: $1,442 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,840 · Education: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,840.09 |
| Education | $532.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,033.86 | 2021-2025 | Imfinzi, Tezspire, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $743.89 | 2022-2024 | Opdivo |
| Lilly USA, LLC | $743.65 | 2021-2024 | Verzenio |
| Incyte Corporation | $311.83 | 2021-2022 | |
| Seagen INC. | $289.72 | 2022-2023 | Padcev |
| Regeneron Healthcare Solutions, INC. | $248.09 | 2022-2024 | Libtayo |
| Medtronic, INC. | $232.14 | 2021-2022 | |
| Amgen INC. | $195.12 | 2023-2025 | Tavneos, Nplate |
| Eisai INC. | $188.38 | 2023-2024 | |
| Janssen Biotech, INC. | $178.94 | 2022 | |
| Alnylam Pharmaceuticals INC. | $177.83 | 2024-2025 | Onpattro |
| Genentech USA, INC. | $136.04 | 2021-2023 | Venclexta |
| Pfizer INC. | $133.20 | 2021-2023 | |
| Boston Scientific Corporation | $133.03 | 2023 | Watchman Flx |
| Abbvie INC. | $120.89 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.60 | 2024 | Jardiance |
| Esperion Therapeutics, INC. | $114.53 | 2021 | |
| Olympus America INC. | $113.51 | 2024 | Single Use Biliary Balloon Dilator, Single Use Aspiration Needle Na-U200h |
| Daiichi Sankyo INC. | $110.28 | 2021 | |
| Novo Nordisk INC | $110.26 | 2021 | |
| Gilead Sciences, INC. | $109.31 | 2025 | Epclusa |
| Novartis Pharmaceuticals Corporation | $93.93 | 2024 | |
| Abbott Laboratories | $75.67 | 2023 | Freestyle Libre 3 |
| Corcept Therapeutics | $67.31 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $66.75 | 2022 | |
| Pharmaessentia USA Corporation | $57.25 | 2024 | Besremi |
| Coloplast Corp | $41.49 | 2023 | Restorelle |
| Edwards Lifesciences Corporation | $19.65 | 2025 | Sapien 3 Ultra Resilia |
| Taiho Oncology, INC. | $15.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Amacker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.